Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer - 25/11/15

Doi : 10.1016/j.ucl.2015.08.005

Aurélie Mbeutcha, MD ^a,^b, Ilaria Lucca, MD ^a,^c, Romain Mathieu, MD ^a,^d, Yair Lotan, MD ^e, Shahrokh F. Shariat, MD ^a,^e,^f,^⁎
^a Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Austria
^b Department of Urology, Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, University of Nice Sophia-Antipolis, 151 Route de Saint-Antoine, Nice 06200, France
^c Department of Urology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, Lausanne 1010, Switzerland
^d Department of Urology, Rennes University Hospital, 2 Rue Henri le Guilloux, Rennes 35000, France
^e Department of Urology, University of Texas Southwestern Medical Center, 5303 Harry Hines Boulevard #110, Dallas, TX 75235, USA
^f Department of Urology, Weill Cornell Medical College, Cornell University, 525 E 68th St, New York, NY 10011, USA

^∗Corresponding author. Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, Vienna A-1090, Austria.

Résumé

The standard of care for detection and surveillance of bladder cancer consists of cytology and cystoscopy, but both examinations suffer from many limitations, including issues related to accuracy, invasiveness, and cost. Several noninvasive methods for detection and surveillance of bladder cancer have been developed and urine-based biomarkers seem the most promising. This nonsystematic review critically analyzes the commercially available biomarkers and highlights some upcoming investigational biomarkers. To date, none of these biomarkers has sufficient validation to serve as a reliable alternative to cystoscopy.

Le texte complet de cet article est disponible en PDF.

Keywords : Bladder cancer, Transitional cell carcinoma, Urothelial carcinoma, Urinary biomarkers, Urine, Detection, Surveillance, Follow-up

Plan

Key points

Introduction

Material and method

Commercially available biomarkers

Food and Drug Administration–Approved Biomarkers

Non–Food and Drug Administration–Approved Biomarkers

Investigational biomarkers

Protein-Based and Cell-Based Biomarkers

Gene-Based Biomarkers

Summary

	Funding Sources: Bourse des Amis de la Faculté de Médecine de Nice (A. Mbeutcha); Nil (I. Lucca, R. Mathieu, Y. Lotan, and S.F. Shariat).
	Conflict of Interest: Nil (A. Mbeutcha, I. Lucca, R. Mathieu, and S.F. Shariat); Research with Abbott, Pacific Edge, Cepheid, MDxHealth, and Nucleix (Y. Lotan).

Export

Vol 43 - N° 1

P. 47-62 - février 2016 Retour au numéro

Article précédent

4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening
Michelle L. McDonald, J. Kellogg Parsons

| Article suivant

Emerging Bladder Cancer Biomarkers and Targets of Therapy
George J. Netto, Laura J. Tafe

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer - 25/11/15

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL